DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Generic Name: desvenlafaxine succinate

Summary for Generic Name: desvenlafaxine succinate

Tradenames:1
Patents:2
Applicants:1
NDAs:1
Drug Master File Entries: see list12
Suppliers: see list6

Clinical Trials for: desvenlafaxine succinate

Desvenlafaxine Succinate (DVS) for Major Depressive Disorder (MDD) in Midlife Men and Women
Status: Recruiting Condition: Major Depressive Disorder; Menopausal Staging and Vasomotor Symptoms (for Females)

Retrospective Study Evaluating The Current Utilization Of Desvenlafaxine Succinate Sustained-Release (Pristiq) Among Psychiatrists And Primary Care Physicians In The Treatment Of Patients With Major Depressive Disorder
Status: Completed Condition: Major Depressive Disorder

Study Evaluating the Safety, Tolerability and Pharmacokinetics of Desvenlafaxine Succinate SR in Healthy Chinese Male and Females
Status: Completed Condition: Healthy

Desvenlafaxine in Opioid-Dependent Patients
Status: Recruiting Condition: Depression; Opioid Dependence

Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Status: Completed Condition: Major Depressive Disorder

Desvenlafaxine Monotherapy in Dysthymia
Status: Active, not recruiting Condition: Dysthymic Disorder

Efficacy and Safety Study of Desvenlafaxine in the Treatment of Vascular Depression
Status: Not yet recruiting Condition: Vascular Depression

Open Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Aripiprazole When Coadministered To Healthy Subjects
Status: Completed Condition: Pharmacokinetics; Cytochrome P-450 CYP2D6; CYP3A4 Protein, Human

Desvenlafaxine vs. Placebo Treatment of Chronic Depression
Status: Recruiting Condition: Dysthymic Disorder; Dysthymia; Chronic Depressive Disorder

Pharmacokinetics and Safety of Desvenlafaxine in Korean Healthy Subjects Following Single and Multiple Oral Doses of Desvenlafaxine Succinate Sustained Release Tablet
Status: Completed Condition: Major Depressive Disorder

Courtesy of ClinicalTrials.org
See more clinical trials for this drug

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Wyeth Pharms Inc
PRISTIQ
desvenlafaxine succinate
TABLET, EXTENDED RELEASE;ORAL021992Feb 29, 2008RXYes6,673,838<disabled>YMAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
Wyeth Pharms Inc
PRISTIQ
desvenlafaxine succinate
TABLET, EXTENDED RELEASE;ORAL021992Feb 29, 2008RXYes6,673,838<disabled>YFOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION
Wyeth Pharms Inc
PRISTIQ
desvenlafaxine succinate
TABLET, EXTENDED RELEASE;ORAL021992Feb 29, 2008RXYes8,269,040<disabled>Y
Wyeth Pharms Inc
PRISTIQ
desvenlafaxine succinate
TABLET, EXTENDED RELEASE;ORAL021992Feb 29, 2008RXYes<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc